China Isotope & Radiation 

HK$18.83
1
+HK$0.17+0.91% Friday 08:05

Statistics

Day High
19.14
Day Low
18.66
52W High
24.4
52W Low
11.16
Volume
62,800
Avg. Volume
-
Mkt Cap
6.02B
P/E Ratio
12.25
Dividend Yield
2.26%
Dividend
0.43

Upcoming

Dividends

2.26%Dividend Yield
Dec 25
HK$0.09
Aug 25
HK$0.34
Nov 24
HK$0.08
Aug 24
HK$0.34
Aug 23
HK$0.48
10Y Growth
N/A
5Y Growth
14.4%
3Y Growth
-3.85%
1Y Growth
N/A

Earnings

27MarExpected
Q2 2023
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
0.43
0.76
1.1
1.43
Expected EPS
N/A
Actual EPS
N/A

Financials

5.37%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
16.15BRevenue
867.29MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1763.HK. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Chengdu Kanghong Pharmaceutical Group
002773.SZ
Mkt Cap16.85B
Chongqing Zhifei Biological Products Co., Ltd. operates in the biopharmaceutical sector focusing on products that could overlap with the medical isotopes and radiation products offered by China Isotope & Radiation.
Changchun High-Tech Industry (Group).
000661.SZ
Mkt Cap65.8B
Tasly Pharmaceutical Group Co., Ltd. engages in the R&D and manufacturing of pharmaceutical products, including those in the biopharmaceutical and radiopharmaceutical sectors.
Hangzhou Tigermed Consulting
300347.SZ
Mkt Cap78.26B
Tonghua Dongbao Pharmaceutical Co., Ltd. competes in the pharmaceutical sector, particularly in biopharmaceuticals, which can include radiation-based treatments.
Livzon Pharmaceutical Group
000513.SZ
Mkt Cap30.26B
Lepu Medical Technology (Beijing) Co., Ltd. manufactures medical equipment and pharmaceuticals, including those for diagnostic and therapeutic uses involving radiation, competing with China Isotope & Radiation.
Lepu Medical Technology (Beijing).
300003.SZ
Mkt Cap43.1B
LianBio, focusing on biopharmaceuticals, has interests in areas that could compete with the radiopharmaceutical aspects of China Isotope & Radiation's business.
BGI Genomics.
300676.SZ
Mkt Cap30.09B
Changchun High & New Technology Industries (Group) Inc. operates in the biotechnology and healthcare sectors, potentially competing in the radiopharmaceutical space.
Shenzhen Kangtai Biological Products
300601.SZ
Mkt Cap34.83B
Wuhan Humanwell Healthcare (Group) Co., Ltd. engages in the healthcare industry, including pharmaceuticals that may compete with the products of China Isotope & Radiation.

About

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Independent Clinical Medical and Laboratory Services, and Other Business. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment provides medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization; and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment sells radiation therapy equipment; and provides related maintenance services. The Independent Clinical Medical and Laboratory Services, and Other Business segment provides independent clinical laboratory services with respect to hepatitis, endocrine, bone metabolism, cardiovascular disease, diabetes, and other diseases to hospitals and other medical institutions. The company was founded in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation.
Show more...
CEO
Mr. Suohui Wang
Employees
3244
Country
Hong Kong
ISIN
CNE1000031F4

Listings

0 Comments

Share your thoughts

FAQ

What is China Isotope & Radiation stock price today?
The current price of 1763.HK is HK$18.83 HKD — it has increased by +0.91% in the past 24 hours. Watch China Isotope & Radiation stock price performance more closely on the chart.
What is China Isotope & Radiation stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange China Isotope & Radiation stocks are traded under the ticker 1763.HK.
Is China Isotope & Radiation stock price growing?
1763.HK stock has risen by +4.03% compared to the previous week, the month change is a -9.21% fall, over the last year China Isotope & Radiation has showed a +63.45% increase.
What is China Isotope & Radiation market cap?
Today China Isotope & Radiation has the market capitalization of 6.02B
When is the next China Isotope & Radiation earnings date?
China Isotope & Radiation is going to release the next earnings report on August 27, 2026.
What is China Isotope & Radiation revenue for the last year?
China Isotope & Radiation revenue for the last year amounts to 16.15B HKD.
What is China Isotope & Radiation net income for the last year?
1763.HK net income for the last year is 867.29M HKD.
Does China Isotope & Radiation pay dividends?
Yes, 1763.HK dividends are paid semi-annual. The last dividend per share was 0.09 HKD. As of today, Dividend Yield (FWD)% is 2.26%.
How many employees does China Isotope & Radiation have?
As of April 25, 2026, the company has 3,244 employees.
In which sector is China Isotope & Radiation located?
China Isotope & Radiation operates in the Health & Wellness sector.
When did China Isotope & Radiation complete a stock split?
China Isotope & Radiation has not had any recent stock splits.
Where is China Isotope & Radiation headquartered?
China Isotope & Radiation is headquartered in Beijing, Hong Kong.